6 results match your criteria: "centre de référence des maladies autoimmunes systemiques rares Est Sud-Ouest (RESO)[Affiliation]"
Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?
Arthritis Care Res (Hoboken)
January 2024
University Hospital Zurich, University of Zurich, Zurich, Switzerland and Oslo University Hospital, Oslo, Norway.
Article Synopsis
- The study investigated the outcomes of patients with systemic sclerosis (SSc) who contracted COVID-19 across different waves of the pandemic, highlighting a lack of data for this specific group.
- A total of 333 SSc patients were analyzed, revealing a reduction in severe outcomes, hospitalizations, and deaths from wave 1 to waves 2 and 3.
- The findings suggest that younger demographics, lower use of high-dose corticosteroids, and possibly improved healthcare responses contributed to better outcomes for SSc patients as the pandemic progressed.
Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey.
Ther Adv Musculoskelet Dis
May 2021
Service de Rhumatologie, Centre National de Référence des Maladies Autoimmunes et Systémiques Rares (RESO), Hôpital de Hautepierre, 1 Avenue Molière BP 83049, Strasbourg Cedex, 67098, France.
Background: Antimalarial agents (AMs), mainly hydroxychloroquine (HCQ) and chloroquine, are the cornerstone of treatment of cutaneous and systemic lupus erythematosus. However, many aspects of AM prescription remain empirical. The aim of this study was to assess the modalities of AM prescription among physicians treating patients with lupus and to verify the assumption that AM use is heterogeneous and frequently at variance with international guidelines.
View Article and Find Full Text PDFPatterns of fatigue and association with disease activity and clinical manifestations in systemic lupus erythematosus.
Rheumatology (Oxford)
June 2021
Centre National de Référence des Maladies Autoimmunes Systémiques Rares Est Sud-Ouest (RESO)-LUPUS, European Reference Networks (ERN) ReCONNET and RITA, Strasbourg, France.
Objective: The prevalence of fatigue is high in patients with systemic lupus erythematosus (SLE). In this study, we used latent class analysis to reveal patterns of fatigue, anxiety, depression and organ involvement in a large international cohort of SLE patients.
Methods: We used the Lupus BioBank of the upper Rhein to analyse patterns of fatigue using latent class analysis (LCA).
Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective study.
Autoimmun Rev
October 2020
Service de Rhumatologie, Hôpitaux Universitaires de Strasbourg, Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, Centre National de Références des Maladies Systémiques et Autoimmunes Rares Est Sud-Ouest (RESO), Université de Strasbourg, F-67000 Strasbourg, France. Electronic address:
Objective: Fatigue is reported in up to 90% of patients with SLE. This study was conducted to identify the determinants associated with fatigue in a large cohort of patients with SLE, as well as to provide a systematic review of the literature.
Methods: Patients from the Lupus BioBank of the upper Rhein, a large German-French cohort of SLE patients, were included in the FATILUP study if they fulfilled the 1997 ACR criteria for SLE and had Fatigue Scale for Motor and Cognitive Functions scores collected.
The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis.
Joint Bone Spine
May 2019
Service de rhumatologie, centre de référence des maladies autoimmunes systemiques rares Est Sud-Ouest (RESO), hôpital de Hautepierre, 1, avenue Molière BP 83049, 67098 Strasbourg cedex, France; Inserm UMR-S1109, 67098 Strasbourg cedex, France. Electronic address:
Objectives: Relapsing polychondritis is a rare, multi-systemic and inflammatory condition of unknown origin. We currently lack a core set of measures to assess and follow damage in patients suffering from this condition. Our primary aim was to derive a disease-specific damage measuring tool for relapsing polychondritis, the Relapsing Polychondritis Damage Index (RPDAM).
View Article and Find Full Text PDF